<img src="https://ml.globenewswire.com/Resource/Download/908fb457-7f8e-4a08-9081-5565e3dfb3d7?size=2" nborder="0" align="left" hspace="5" vspace="5" title="22157.jpg" alt="Company Logo"/>Dublin, Aug. 18, 2026 <a href="https://www.globenewswire.com" target="_blank">(GLOBE NEWSWIRE)</a> -- The <a href="https://www.researchandmarkets.com/reports/6260355/generic-injectables-market-share-analysis?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=f8pjpg&amp;utm_campaign=2328006+-+Generic+Injectables+Market+Research+Report+2026+-+Revenue+to+Reach+%24285.61+Billion+by+2031%2c+Driven+by+Patent+Expirations+and+Biosimilar+Growth&amp;utm_exec=jocamsai" rel="nofollow" target="_blank" title="Generic Injectables - Market Share Analysis, Industry Trends &amp; Statistics, Growth Forecasts (2026-2031)">"Generic Injectables - Market Share Analysis, Industry Trends &amp; Statistics, Growth Forecasts (2026-2031)"</a> has been added to ResearchAndMarkets.com's offering. The global generic injectables market was valued at USD 131.68 billion in 2025 and is projected to increase from USD 149.82 billion in 2026 to USD 285.61 billion by 2031. The market is expected to register a compound annual growth rate of 13.77% during the 2026-2031 forecast period. Market growth is supported by branded injectable patent expirations, rising demand for affordable oncology and anti-infective therapies, expanding biosimilar approvals, and growing hospital adoption of ready-to-use formats. The report analyzes the market by product type, molecule type, therapeutic area, route of administration, distribution channel, and geography, with forecasts provided in USD. Patent Expirations Accelerate Generic Injectable Launches A broad wave of injectable drug exclusivity losses is creating opportunities for abbreviated approvals and faster portfolio expansion. The impact is particularly significant in oncology, supportive care, and acute care, where hospitals require clinically appropriate alternatives as branded products lose patent protection. The U.S. Food and Drug Administration approved four first generic injectable drugs during the first quarter of 2026, including bortezomib powder for injection and aprepitant injection. These approvals demonstrate continued regulatory activity across sterile drug categories. High technical and regulatory barriers may also limit the number of qualified competitors, supporting more durable demand for early market entrants with compliant manufacturing capacity. Oncology and Anti-Infective Demand Supports Market Expansion Oncology accounted for 33.26% of generic injectables market revenue in 2025 and is forecast to grow at a CAGR of 16.55% through 2031. Demand is rising for cost-effective injectable cancer therapies that meet stringent quality, availability, and supply continuity requirements. Anti-infective injectables also remain essential across hospital settings, including carbapenems, beta-lactams, antifungals, and other acute care treatments. Procurement strategies increasingly consider manufacturing quality, supplier diversity, and replenishment reliability alongside pricing. This trend benefits manufacturers that can provide consistent supply in clinically sensitive and shortage-prone categories. Sterile Fill-Finish Capacity Remains a Key Constraint Limited sterile fill-finish capacity continues to restrict the commercialization of generic injectable products. Aseptic manufacturing requires specialized equipment, extensive validation, and longer production ramp-up periods. According to a 2024 Parenteral Drug Association survey concerning EU GMP Annex 1 implementation, 40% of responding facilities required timeline extensions, while 30% reported upgrade investments exceeding USD 2 million. These requirements may create scheduling, validation, and regulatory bottlenecks when product launches, shortage responses, and facility upgrades occur simultaneously. Manufacturers with approved products may therefore face delays in converting regulatory clearances into dependable commercial supply. Additional market factors include: <ul><li>Biosimilar and complex injectable approvals expanding addressable demand</li><li>Hospital preference for ready-to-use and pre-administration formats</li><li>Tender-driven price compression and group purchasing organization consolidation</li></ul> Product and Molecule Segment Insights Vials represented 45.31% of market revenue in 2025, reflecting their established use in oncology infusion, anti-infective treatment, and institutional care. Prefilled syringes are forecast to grow at a CAGR of 16.38% through 2031 as healthcare providers seek fewer preparation steps, safer handling, and greater compatibility with subcutaneous therapies. The positive June 2026 Committee for Medicinal Products for Human Use opinion for Nylaspeg, a pegfilgrastim biosimilar supplied in a 6 mg prefilled syringe, reflects the increasing integration of ready-to-use delivery formats into biosimilar launches. Ampoules retain demand in anesthesia and emergency medicine, while IV bags and large-volume parenterals remain important in critical care, electrolyte replacement, and parenteral nutrition. Cartridges support insulin and GLP-1 delivery systems where device compatibility is a central requirement. Small-molecule generics held 58.24% of the generic injectables market in 2025. This segment includes IV antibiotics, cytotoxic chemotherapy, analgesics, and cardiovascular injectables. Large-molecule injectables and biosimilar generics are projected to expand at a CAGR of 15.52% through 2031, supported by growing investment in biologic development, analytical capabilities, and sterile manufacturing. The FDA approved 18 injectable biosimilars in 2025, bringing the total number of approved biosimilars to 90 as of early 2026. In June 2026, Aurobindo Pharma launched the TheraNym biologics contract manufacturing facility in Telangana, featuring 15-kiloliter bioreactors and aseptic fill-finish capabilities. Such investments illustrate the industry's shift toward complex, higher-value injectable products. Regional Generic Injectables Market Outlook North America held 36.78% of global market revenue in 2024, supported by advanced hospital infrastructure, established regulatory pathways, automated compounding systems, and growing adoption of ready-to-administer products. Healthcare systems are investing in technologies and delivery formats designed to reduce medication errors and clinical workloads. Asia-Pacific is expected to record the fastest regional growth, with a projected CAGR of 16.43%. India's Production Linked Incentive program is directing approximately USD 2 billion toward sterile manufacturing capacity and technology upgrades. China's increasing alignment with International Council for Harmonisation guidelines is also strengthening export credibility. Japan, South Korea, and Australia contribute through biosimilar adoption and supportive pricing frameworks. Europe remains an important market due to its established pharmaceutical manufacturing base, broad patient access, and stringent quality requirements. Revised EU GMP Annex 1 requirements are increasing compliance costs while encouraging stronger contamination-control and supply-reliability standards. Germany and France lead regional adoption of automated fill-finish systems, while Eastern Europe continues to attract contract manufacturing investment. Key Topics Covered 1 Introduction 1.1 Study Assumptions &amp; Market Definition 1.2 Scope of the Study 2 Research Methodology 3 Executive Summary 4 Market Landscape 4.1 Market Overview 4.2 Market Drivers 4.2.1 Patent Cliff Wave Accelerating Generic Launches 4.2.2 Rising Demand for Sterile Affordable Oncology and Anti-Infective Therapies 4.2.3 Hospital Preference for Ready-to-Use and Pre-Administration Formats 4.2.4 Biosimilar and Complex Injectable Approvals Broadening Addressable Demand 4.2.5 AI-Assisted Formulation and Analytical Development Shortening Development Cycles 4.2.6 Lyophilized-to-Liquid Conversion Lowering Cold-Chain and COGS Burden 4.3 Market Restraints 4.3.1 Sterile Fill-Finish Capacity Bottlenecks 4.3.2 Tender-Led Price Compression and GPO Consolidation 4.3.3 Annex 1 and Sterility Compliance Cost Escalation 4.3.4 Volatile Supply of Type I Glass and COP Components 4.4 Supply Chain Analysis 4.5 Regulatory Landscape 4.6 Technological Outlook 4.7 Porter's Five Forces Analysis 4.7.1 Bargaining Power of Suppliers 4.7.2 Bargaining Power of Buyers 4.7.3 Threat of New Entrants 4.7.4 Threat of Substitutes 4.7.5 Industry Rivalry 5 Market Size &amp; Growth Forecasts (Value, USD) 5.1 By Product Type 5.1.1 Vials 5.1.2 Ampoules 5.1.3 Prefilled Syringes 5.1.4 Cartridges 5.1.5 IV Bags and Large Volume Parenterals 5.2 By Molecule Type 5.2.1 Small-Molecule Generics 5.2.2 Large-Molecule Injectables and Biosimilar Generics 5.3 By Therapeutic Area 5.3.1 Oncology 5.3.2 Anti-Infectives 5.3.3 Cardiovascular 5.3.4 Diabetes and Metabolic Disorders 5.3.5 Central Nervous System Disorders 5.3.6 Other Therapeutic Areas 5.4 By Route of Administration 5.4.1 Intravenous 5.4.2 Intramuscular 5.4.3 Subcutaneous 5.4.4 Other Routes of Administration 5.5 By Distribution Channel 5.5.1 Hospital Pharmacies 5.5.2 Retail and Mail-Order Pharmacies 5.5.3 Online Pharmacies 5.5.4 Other Distribution Channel 5.6 By Geography 5.6.1 North America 5.6.1.1 United States 5.6.1.2 Canada 5.6.1.3 Mexico 5.6.2 Europe 5.6.2.1 Germany 5.6.2.2 United Kingdom 5.6.2.3 France 5.6.2.4 Italy 5.6.2.5 Spain 5.6.2.6 Rest of Europe 5.6.3 Asia-Pacific 5.6.3.1 China 5.6.3.2 Japan 5.6.3.3 India 5.6.3.4 Australia 5.6.3.5 South Korea 5.6.3.6 Rest of Asia-Pacific 5.6.4 Middle East and Africa 5.6.4.1 GCC 5.6.4.2 South Africa 5.6.4.3 Rest of Middle East and Africa 5.6.5 South America 5.6.5.1 Brazil 5.6.5.2 Argentina 5.6.5.3 Rest of South America 6 Competitive Landscape 6.1 Market Concentration 6.2 Market Share Analysis 6.3 Company Profiles (includes Global Level Overview, Market Level Overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share, Products and Services, Recent Developments) 6.3.1 Accord Healthcare Limited 6.3.2 Apotex Inc. 6.3.3 Aurobindo Pharma Limited 6.3.4 Baxter International Inc. 6.3.5 Cipla Ltd. 6.3.6 Dr. Reddy's Laboratories Ltd. 6.3.7 Endo International plc 6.3.8 Fresenius Kabi 6.3.9 Glenmark Pharmaceuticals Ltd. 6.3.10 Hikma Pharmaceuticals PLC 6.3.11 Intas Pharmaceuticals Ltd. 6.3.12 Lupin Limited 6.3.13 Pfizer Inc. 6.3.14 Sandoz Group AG 6.3.15 Sawai Pharmaceutical Group 6.3.16 STADA Arzneimittel AG 6.3.17 Sun Pharmaceutical Industries Ltd. 6.3.18 Teva Pharmaceutical Industries Ltd. 6.3.19 Viatris Inc. 6.3.20 Zydus Lifesciences Limited 7 Market Opportunities &amp; Future Outlook 7.1 White-Space and Unmet-Need Assessment For more information about this report visit <a href="https://www.researchandmarkets.com/reports/6260355/generic-injectables-market-share-analysis?utm_source=GNE&amp;utm_medium=PressRelease&amp;utm_code=f8pjpg&amp;utm_campaign=2328006+-+Generic+Injectables+Market+Research+Report+2026+-+Revenue+to+Reach+%24285.61+Billion+by+2031%2c+Driven+by+Patent+Expirations+and+Biosimilar+Growth&amp;utm_exec=jocamsai" rel="nofollow" target="_blank" title="">https://www.researchandmarkets.com/r/gm3eo3</a> About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. <pre>CONTACT: 
CONTACT: ResearchAndMarkets.com 
 Laura Wood,Senior Press Manager 
 press@researchandmarkets.com
 For E.S.T Office Hours Call 1-917-300-0470 
 For U.S./ CAN Toll Free Call 1-800-526-8630 
 For GMT Office Hours Call +353-1-416-8900 

</pre> <img alt="" src='https://ml.globenewswire.com/media/YjE0NDJjYzItYmYwOS00OTJiLTk3MDctM2JjODQ5OGFiYTEyLTEwMjY3MzctMjAyNi0wOC0xOC1lbg==/tiny/Research-and-Markets.png' referrerpolicy='no-referrer-when-downgrade' />

GlobeNewswire Inc.

Generic Injectables Market Research Report 2026 - Revenue to Reach $285.61 Billion by 2031, Driven by Patent Expirations and Biosimilar Growth

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn